Redeye updates its estimates and valuation following Serstech's Q1 2024 report. Overall, the financials were in line with our estimates and the orders that had been announced beforehand. We make small downward revisions to our fair value range and look for new order announcements to derisk our estimates and close the c30% gap between the share price and our Base Case.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Serstech Q2 - Product launch and stable delivery

© Modular Finance, source Nordic Press Releases